Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics

December 06, 2023 00:21:48
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics
COR2ED - Oncology Medical Conversation
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics

Dec 06 2023 | 00:21:48

/

Show Notes

Dr. Tanya Dorff (City of Hope Comprehensive Cancer Center, Los Angeles, USA) and Dr. Phillip Koo (Banner MD Anderson Cancer Center, Arizona, USA) discuss the latest developments in the field of radiopharmaceuticals and their use in Prostate Cancer.

This second episode focuses on PSMA-targeted radiopharmaceuticals and how PSMA can be a target for imaging as well as for therapies. Efficacy and safety data from the phase 2 TheraP study are discussed which investigated lutetium-PSMA versus cabazitaxel in patients with mCRPC who had progressed on docetaxel. The experts also discuss the ongoing VISION trial and what the results may mean for clinical practice as well as other ongoing trials looking at lutetium-PSMA in combination with other prostate cancer therapies such as PARP inhibitors, immunotherapies, hormonal therapies and chemotherapy. Treatment sequencing is also considered in terms of where lutetium-PSMA fits into clinical practice for mCRPC patients and how the treatment compares to Radium-223.

Other Episodes

Episode

December 07, 2023 00:22:35
Episode Cover

Precision oncology: An overview of tumour agnostic therapies

What are tumour agnostic cancer treatments and which biomarkers do they target? Join Prof. David Hong (Medical Oncologist at MD Anderson Cancer Center, Houston,...

Listen

Episode

December 06, 2023 00:21:28
Episode Cover

Precision oncology: Detection and treatment of TRK fusion-positive lung cancers

In this medical education podcast, NTRK CONNECT members Assoc. Prof. Caterina Marchiò (University of Turin, Italy) and Prof. Christian Rolfo (Center of Thoracic Oncology...

Listen

Episode

December 06, 2023 00:19:56
Episode Cover

Multiple Myeloma: Choosing the best treatment regimen in patients with high-risk cytogenetics - Part 3

In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Lesokhin (Associate Attending on...

Listen